Background: Nuclear factor of activated T cells (NFAT) is required for the differentiation of Th2 responses, so we examined its role in mouse experimental asthma and tested the hypothesis that an NFAT blockade with a decoy against NFAT can prevent asthma progression. Objective: To determine the effects of the NFAT decoy oligodeoxynucleotides (ODNs) on the development of airway inflammation, we designed a novel ribbon-type ODN containing two binding sites for NFAT in a single decoy molecule without an open end, which is more stable than a conventional decoy, and largely preserved its structural integrity in the presence of nucleases. Methods: Ribbon-type NFAT decoy ODNs were transfected into ovalbumin (OVA)-sensitized CD3+ T cells in vitro. OVA-immunized mice received these cells by intraperitoneal injection. Airway hyperreactivity (AHR) was measured and the transfected CD3+ T cells’ responses to the airways were characterized. Results: Development of AHR after OVA challenge was effectively abolished after adoptive transfer of ribbon-type NFAT decoy ODN transfected CD3+ T cells. Transfer of ribbon-type decoy significantly reduced the number of inflammatory cells and the concentrations of IL-4, IL-5 and IL-13, but not IFN-γ, in the bronchoalveolar lavage of the recipient mice. Conclusion: These results suggest the inhibitory effect of ribbon-type decoy ODNs against NFAT on the induction of bronchial asthma. Adoptively transferred CD3+ T cells, which are transfected with NFAT decoy, may be an effective strategy for the treatment of asthma.

Keywords:
Nuclear factor of activated T cells, Transcription factor, T helper 2 cytokines, Adoptive transfer, Decoy, Gene therapy, Allergic airway inflammation, Experimental asthma
1.
Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, Corrigan C, Durham SR, Kay AB: Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992;326:298–304.
2.
Chuvpilo S, Schomberg C, Gerwig R, Heinfling A, Reeves R, Grummt F, Serfling E: Multiple closely-linked NFAT/octamer and HMG I(Y) binding sites are part of the interleukin-4 promoter. Nucleic Acids Res 1993;21:5694–5704.
3.
Lee HJ, Masuda ES, Arai N, Arai K, Yokota T: Definition of cis-regulatory elements of the mouse interleukin-5 gene promoter. Involvement of nuclear factor of activated T cell-related factors in interleukin-5 expression. J Biol Chem 1995;270:17541–17550.
4.
Masuda ES, Tokumitsu H, Tsuboi A, Shlomai J, Hung P, Arai K, Arai N: The granulocyte-macrophage colony-stimulating factor promoter cis-acting element CLE0 mediates induction signals in T cells and is recognized by factors related to AP1 and NFAT. Mol Cell Biol 1993;13:7399–7407.
5.
Goldfeld AE, McCaffrey PG, Strominger JL, Rao A: Identification of a novel cyclosporin-sensitive element in the human tumor necrosis factor α gene promoter. J Exp Med 1993;178:1365–1379.
6.
McCaffrey PG, Goldfeld AE, Rao A: The role of NFATp in cyclosporin A-sensitive tumor necrosis factor-α gene transcription. J Biol Chem 1994;269:30445–30450.
7.
Dolganov G, Bort S, Lovett M, Burr J, Schubert L, Short D, McGurn M, Gibson C, Lewis DB: Coexpression of the interleukin-13 and interleukin-4 genes correlates with their physical linkage in the cytokine gene cluster on human chromosome 5q23–31. Blood 1996;87:3316–3326.
8.
Tsytsykova AV, Tsitsikov EN, Geha RS: The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. J Biol Chem 1996;271:3763–3770.
9.
McCaffrey PG, Luo C, Kerppola TK, Jain J, Badalian TM, Ho AM, Burgeon E, Lane WS, Lambert JN, Curran T, Verdine GL, Rao A, Hogan PG: Isolation of the cyclosporin-sensitive T cell transcription factor NFATp. Science 1993;262:750–754.
10.
Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, Admon A, Crabtree GR: NF-AT components define a family of transcription factors targeted in T-cell activation. Nature 1994;369:497–502.
11.
Ho SN, Thomas DJ, Timmerman LA, Li X, Francke U, Crabtree GR: NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity. J Biol Chem 1995;270:19898–19907.
12.
Hoey T, Sun YL, Williamson K, Xu X: Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. Immunity 1995;2:461–472.
13.
Masuda ES, Naito Y, Tokumitsu H, Campbell D, Saito F, Hannum C, Arai K, Arai N: NFATx, a novel member of the nuclear factor of activated T cells family that is expressed predominantly in the thymus. Mol Cell Biol 1995;15:2697–2706.
14.
Rao A, Luo C, Hogan PG: Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997;15:707–747.
15.
Yoshida H, Nishina H, Takimoto H, Marengère LE, Wakeham AC, Bouchard D, Kong YY, Ohteki T, Shahinian A, Bachmann M, Ohashi PS, Penninger JM, Crabtree GR, Mak TW: The transcription factor NF-ATc1 regulates lymphocyte proliferation and Th2 cytokine production. Immunity 1998;8:115–124.
16.
Ranger AM, Hodge MR, Gravallese EM, Oukka M, Davidson L, Alt FW, de la Brousse FC, Hoey T, Grusby M, Glimcher LH: Delayed lymphoid repopulation with defects in IL-4-driven responses produced by inactivation of NF-ATc. Immunity 1998;8:125–134.
17.
Xanthoudakis S, Viola JP, Shaw KT, Luo C, Wallace JD, Bozza PT, Luk DC, Curran T, Rao A: An enhanced immune response in mice lacking the transcription factor NFAT1. Science 1996;272:892–895.
18.
Viola JP, Kiani A, Bozza PT, Rao A: Regulation of allergic inflammation and eosinophil recruitment in mice lacking the transcription factor NFAT1: role of interleukin-4 (IL-4) and IL-5. Blood 1998;91:2223–2230.
19.
Diehl S, Krahl T, Rinaldi L, Norton R, Irvin CG, Rincón M: Inhibition of NFAT specifically in T cells prevents allergic pulmonary inflammation. J Immunol 2004;172:3597–3603.
20.
Bielinska A, Shivdasani RA, Zhang LQ, Nabel GJ: Regulation of gene expression with double-stranded phosphorothioate oligonucleotides. Science 1990;250:997–1000.
21.
Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T: In vivo transfection of cis element ‘decoy’ against nuclear factor-ĸB binding site prevents myocardial infarction. Nat Med 1997;3:894–899.
22.
Quarcoo D, Weixler S, Groneberg D, Joachim R, Ahrens B, Wagner AH, Hecker M, Hamelmann E: Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. J Allergy Clin Immunol 2004;114:288–295.
23.
Desmet C, Gosset P, Henry E, Garzé V, Faisca P, Vos N, Jaspar F, Mélotte D, Lambrecht B, Desmecht D, Pajak B, Moser M, Lekeux P, Bureau F: Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1. Am J Respir Crit Care Med 2005;172:671–678.
24.
Henry SP, Bolte H, Auletta C, Kornbrust DJ: Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a four-week study in cynomolgus monkeys. Toxicology 1997;120:145–155.
25.
Mattes J, Yang M, Mahalingam S, Kuehr J, Webb DC, Simson L, Hogan SP, Koskinen A, McKenzie AN, Dent LA, Rothenberg ME, Matthaei KI, Young IG, Foster PS: Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. J Exp Med 2002;195:1433–1444.
26.
Yamauchi K, Piao HM, Nakadate T, Shikanai T, Nakamura Y, Ito H, Mouri T, Kobayashi H, Maesawa C, Sawai T, Ohtsu H, Inoue H: Enhanced goblet cell hyperplasia in HDC knockout mice with allergic airway inflammation. Allergol Int 2009;58:125–134.
27.
Bhattacharya S, Stout BA, Bates ME, Bertics PJ, Malter JS: Granulocyte macrophage colony-stimulating factor and interleukin-5 activate STAT5 and induce CIS1 mRNA in human peripheral blood eosinophils. Am J Respir Cell Mol Biol 2001;24:312–316.
28.
Nakamura Y, Esnault S, Maeda T, Kelly EA, Malter JS, Jarjour NN: Ets-1 regulates TNF-α-induced matrix metalloproteinase-9 and tenascin expression in primary bronchial fibroblasts. J Immunol 2004;172:1945–1952.
29.
Takahashi S, Nakamura Y, Nishijima T, Sakurai S, Inoue H: Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome. Respir Med 2005;99:1125–1131.
30.
Bates JH, Irvin CG: Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol 2003;94:1297–1306.
31.
Nakamura Y, Hoshino M: TH2 cytokines and associated transcription factors as therapeutic targets in asthma. Curr Drug Targets Inflamm Allergy 2005;4:267–270.
32.
Kunugiza Y, Tomita T, Tomita N, Morishita R, Yoshikawa H: Inhibitory effect of ribbon-type NF-ĸB decoy oligodeoxynucleotides on osteoclast induction and activity in vitro andin vivo. Arthritis Res Ther 2006;8:R103.
33.
Christodoulopoulos P, Cameron L, Nakamura Y, Lemière C, Muro S, Dugas M, Boulet LP, Laviolette M, Olivenstein R, Hamid Q: TH2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression. J Allergy Clin Immunol 2001;107:586–591.
34.
Takemoto N, Kamogawa Y, Jun Lee H, Kurata H, Arai KI, O’Garra A, Arai N, Miyatake S: Chromatin remodeling at the IL-4/IL-13 intergenic regulatory region for Th2-specific cytokine gene cluster. J Immunol 2000;165:6687–6691.
35.
Klein-Hessling S, Jha MK, Santner-Nanan B, Berberich-Siebelt F, Baumruker T, Schimpl A, Serfling E: Protein kinase A regulates GATA-3-dependent activation of IL-5 gene expression in Th2 cells. J Immunol 2003;170:2956–2961.
36.
Kishikawa H, Sun J, Choi A, Miaw SC, Ho IC: The cell type-specific expression of the murine IL-13 gene is regulated by GATA-3. J Immunol 2001;167:4414–4420.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.